JP2024543372A - ねじれ形3種脂質修飾核酸化合物 - Google Patents

ねじれ形3種脂質修飾核酸化合物 Download PDF

Info

Publication number
JP2024543372A
JP2024543372A JP2024527320A JP2024527320A JP2024543372A JP 2024543372 A JP2024543372 A JP 2024543372A JP 2024527320 A JP2024527320 A JP 2024527320A JP 2024527320 A JP2024527320 A JP 2024527320A JP 2024543372 A JP2024543372 A JP 2024543372A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
independently
membered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543372A5 (cg-RX-API-DMAC10.html
Inventor
アラーソン,チャールズ
サッコウ,アーサー,ティー.
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024543372A publication Critical patent/JP2024543372A/ja
Publication of JP2024543372A5 publication Critical patent/JP2024543372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2024527320A 2021-11-15 2022-11-14 ねじれ形3種脂質修飾核酸化合物 Pending JP2024543372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279270P 2021-11-15 2021-11-15
US63/279,270 2021-11-15
PCT/US2022/079790 WO2023086979A1 (en) 2021-11-15 2022-11-14 Staggered triple lipid-modified nucleic acid compounds

Publications (2)

Publication Number Publication Date
JP2024543372A true JP2024543372A (ja) 2024-11-21
JP2024543372A5 JP2024543372A5 (cg-RX-API-DMAC10.html) 2025-11-27

Family

ID=86336682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527320A Pending JP2024543372A (ja) 2021-11-15 2022-11-14 ねじれ形3種脂質修飾核酸化合物

Country Status (10)

Country Link
US (1) US20250027082A1 (cg-RX-API-DMAC10.html)
EP (1) EP4433064A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024543372A (cg-RX-API-DMAC10.html)
KR (1) KR20240103016A (cg-RX-API-DMAC10.html)
CN (1) CN118215484A (cg-RX-API-DMAC10.html)
AU (1) AU2022387688A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235447A1 (cg-RX-API-DMAC10.html)
IL (1) IL312217A (cg-RX-API-DMAC10.html)
MX (1) MX2024005742A (cg-RX-API-DMAC10.html)
WO (1) WO2023086979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026163078A1 (en) 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7583712B2 (ja) * 2018-05-30 2024-11-14 ノバルティス アーゲー 脂質修飾された核酸化合物および方法
JP2023503644A (ja) * 2019-11-27 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Also Published As

Publication number Publication date
US20250027082A1 (en) 2025-01-23
CN118215484A (zh) 2024-06-18
MX2024005742A (es) 2024-05-27
EP4433064A4 (en) 2026-07-22
KR20240103016A (ko) 2024-07-03
AU2022387688A1 (en) 2024-04-11
IL312217A (en) 2024-06-01
CA3235447A1 (en) 2023-05-19
EP4433064A1 (en) 2024-09-25
WO2023086979A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7583712B2 (ja) 脂質修飾された核酸化合物および方法
EP3094728B1 (en) Chiral design
CN112004928A (zh) 寡核苷酸组合物及其使用方法
JP2022000023A (ja) オリゴヌクレオチド組成物およびその方法
CA3072076A1 (en) Oligonucleotide compositions and methods thereof
CA3037548A1 (en) Oligonucleotide compositions and methods thereof
KR102079284B1 (ko) 올리고뉴클레오티드 유사체의 보론산 접합체
TW202220695A (zh) 寡核苷酸之全身遞送
BR112020007417A2 (pt) molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b
JP7821737B2 (ja) 核酸および半減期モチーフを含む化合物
US12497616B2 (en) Compounds targeting PMP22 for the treatment of Charcot-Marie-Tooth disease
TW201934750A (zh) 包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
JP2000512630A (ja) 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体
JP2024544975A (ja) 分岐した三重脂質修飾核酸化合物
WO2023086979A1 (en) Staggered triple lipid-modified nucleic acid compounds
BR122024013151A2 (pt) Compostos escalonados de ácido nucleico modificado por lipídio triplo, processos de fabricação e usos dos mesmos, célula, composição farmacêutica, e genoma de célula
BR122024015224A2 (pt) Compostos de ácido nucleico modificado por lipídio triplo ramificados, processos de preparação e usos dos mesmos, célula, composição farmacêutica, e genoma celular
TW202102516A (zh) 膦醯基乙酸酯間隙子寡核苷酸
WO2025261378A1 (zh) 一种修饰的核苷化合物及其在寡核苷酸中的应用
CA3129646A1 (en) Novel phosphoramidites

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804